Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). - Lipton,A.; Alvarado,C.; De Boer,R.; Steger,G.G.; Tonkin,K.S.; Kinsey,A.; Fan,M.; Jun,S. (J Clin Oncol, 2006)